Blog

ZuriMed has won the ATiO Early-Stage Pitch Contest at the ATiO Conference 2024 with their innovative Surgical FibreLock Technology. This groundbreaking technology offers new possibilities in surgery and impressed the audience with its efficiency and precision. The victory highlights ZuriMed's position as an uprising company in the medical technology field. Find out more!

Discover the vibrant energy and memorable moments of the ATiO Conference 2024.  Our gallery offers a visual journey through the conference, highlighting the key moments and the people who made them happen. Whether you attended in person or are catching up from afar, these photographs provide a rich, colorful recap of an inspiring gathering.

Members can log in to view the gallery now and experience the spirit of ATiO Conference 2024 all over again!

Congratulations to Liposphere Ltd. for emerging as the victorious company among a pool of 14 exceptionally promising contenders in the Early-Stage-Company-Contest at the ATiO Conference 2023!

There are two general types of medical ultrasound: diagnostic and therapeutic. Diagnostic ultrasound is widely used to produce real-time images of the body, including for the determination of musculoskeletal injuries and follow-up of musculoskeletal interventions. Contrastingly, therapeutic ultrasound produces bioeffects within the body, via the direct or indirect interaction of acoustic waves with cells/tissue, with the goal of benefiting patient health.

The ATiO Conference 2023 was a dynamic gathering that brimmed with diverse viewpoints and engaging discussions surrounding advanced therapies in orthopaedics. It served as a catalyst for fresh ideas and opened doors to foster future collaborations. Here's a brief overview of the notable occurrences at the event.

All pictures and impressions taken throughout the course of the ATiO Conference 2023!

Delayed bone healing is still an unsolved clinical problem as confirmed by interviewing orthopaedic clinicians from Charité’s orthopaedic and trauma department. These clinicians state that further therapeutic options to treat complex bone healing scenarios would be highly desirable.

Scientific progress was the overall objective pursued by the HipGen study funded by Tobias Winkler under EU Horizon 2020 (Grant 779293): Its aim was to bring the first regenerative therapy for improved recovery after muscle injury to market approval - time for a recapitulation!